Last reviewed · How we verify
NCT03849521
Plaque Calcium Characterization and Ruptured Plaques
trial testing MRI in Vulnerable Atherosclerotic Plaque in 60 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Li Min |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 1 June 2019 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- MRI — full drug profile →
Conditions studied
- Vulnerable Atherosclerotic Plaque — all drugs for Vulnerable Atherosclerotic Plaque →
Sponsor
Li Min
Who can join
Eligibility, any sex, with Vulnerable Atherosclerotic Plaque. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Recently, ultrashort echo time (UTE) MR, which allows detection of the ultrashort T2 components, has been used to image plaque calcification in ex vivo carotid and coronary arteries. The results demonstrated that UTE images are able to identify plaque calcification and enables accurate quantification of calcium volumes. However, gadolinium-based contrast agents during in vivo CMR could not be performed in these ex vivo study. Agnese et al. believed that calcifications with 18F-NaF PET uptake might be considered to represent dormant areas where on-going mineralization, which is a key sign to identify and localise ruptured and high risk coronary plaque. We, therefore, hypothesize that enhanced carotid calcification presented by UTE MR may be a critical sign for symptomatic patients. In this study, we will investigate the feasibility of enhanced UTE MR in human carotid arteries in vivo. Furthermore, we analyzed the correlation between UTE MR and microcalcification of in the carotid plaques. Based on the diagnostic ability of enhanced UTE MR for microcalcification, we will investigate the potential of enhanced calcification to distinguish symptomatic from asymptomatic patients with carotid atherosclerosis and research the prognostic ability of enhance calcufication in UTE MR.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03849521
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MRI
Trials testing the same drug.
- NCT02831335 — Technical Development of Multi-Parametric Renocerebral MRI · recruiting
- NCT07487870 — Radiographic Evaluation of Tumor Biology During Neoadjuvant Radiotherapy for Sarcoma · NA · not yet recruiting
- NCT07567053 — Repetitive Transcranial Magnetic Stimulation on Motor Function and Meta-Plasticity in Cerebral Palsy: TMS-EEG Study · NA · not yet recruiting
- NCT07537504 — Language Function Reorganization in Patients With Arteriovenous Malformations · not yet recruiting
- NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting
Other Li Min trials
Trials by the same sponsor.
- NCT07171996 — Research on the Optimization of Treatment for Spinal Metastases With Radioactive Particle Implantation Using TPS and Mec · NA · recruiting
- NCT03850938 — Percutaneous Kyphoplasty Using Rotary Cutter in Osteoporotic Vertebral Fractures · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03849521 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Li Min
- Last refreshed: 21 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03849521.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing